TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Reduction of Bacteria in MRSA Positive Ulcers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must have given written informed consent~* Must be 19 years of age or over~* Must have an ulcer or lesion in which the presence of MRSA has been positively identified but which is not clinically infected.~* Must have an Ulcer / Lesion size not to extend beyond the inner borders of the wound cover~Exclusion Criteria:~* Is a female who is pregnant, nursing, or of child bearing potential who is not using an adequate form of contraception (or abstinence)~* Is \< 19 years of age~* Has a clinically infected ulcer~* Has an Ulcer / Lesion that is currently treated or has been treated with a topical antimicrobial agent during 3 days prior to enrolment.~* Has been using systemic antibiotics during 7 days prior to enrolment into this study.~* Has an Ulcer / Lesion which is identified as malignant in origin (e.g., Marjolin's ulcer)~* Has an Ulcer / Lesion size beyond the inner borders of the wound cover~* Is septic or has other signs of an invasive infection~* Has used any other investigational product within 30 days preceding study participation.~* Suffers from a condition, which, in the opinion of the Investigator,would compromise his or her safety.~* Suffers from a condition which, in the opinion of the Investigator, would compromise the quality of the data.~* Has a known allergy to any of the products that are part of this protocol~* Suffers from a condition which, in the opinion of the Investigator, would seriously interfere negatively with the normal parameters of immune response to an infection.~* Is using any of the prohibited concomitant medications or treatments

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nitric Oxide (Type: EXPERIMENTAL): gaseous nitric oxide delivered topically for 30 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Focus on Fibre Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* healthy but overweight/obese (BMI 28-40kg/m2) males and females (post-menopausal, using the oral contraceptive pill or some form of hormonal contraceptive)~* low habitual fibre intake (\<10g/day)~Exclusion Criteria:~Medication exclusion criteria:~* antibiotic use (within the past 3 months due to impact on gut microbiota)~* statins (current)~* aspirin or other NSAIDs or anti-coagulants (current)~* anti-depressants (current)~* smoking or vaping~Medical exclusion criteria:~* Females who are planning to be pregnant, are pregnant or are breastfeeding~* Anyone with food allergies, self-reported food sensitivity or intolerance~* Anyone with coeliac disease or gluten intolerance~* Anyone taking medication which may affect their appetite~* Anyone with an eating disorder~* Anyone with diabetes~* Anyone with a gastrointestinal disorder, kidney disease, liver disease or gout~* Anyone suffering from a psychiatric disorder or any type of substance abuse~* Anyone suffering from unregulated thyroid disease~Other exclusion criteria:~* Anyone following a vegetarian or vegan diet~* Anyone following a weight loss programme (that may be affecting lifestyle, physical activity \& diet)~* Anyone with unsuitable veins for blood sampling~* Anyone who is unable to fluently speak, read and understand English~* Anyone who is unable to comply to an alcohol-free diet for 6 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control - High Fibre - Low Fibre (CTRL - HF - LF) (Type: EXPERIMENTAL): * Phase 1 - CTRL: Control diet with moderate fibre consumption for 13days.~* Phase 2 - HF: ad libitum consumption of HF meals for 13days.~* Phase 3 - LF: ad libitum consumption of LF meals for 13days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A female patient who needs IVF to become pregnant.~* Regular menstrual cycle.~* Antral follicular count (AFC) \> 18~* Following treatment with follitropin beta more than 18 follicles ≥ 11 mm will develop.~Exclusion Criteria:~* Hypersensitivity to the active substance or to any of the medications used.~* Tumors of the ovary, breast, uterus, pituitary or hypothalamus.~* Pregnancy.~* Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause.~* Primary ovarian failure.~* Ovarian cysts or enlarged ovaries.~* A history of Ovarian Hyperstimulation Syndrome (OHSS).~* A previous COS cycle that resulted in more than 30 follicles \> 11 mm measured by ultrasound examination.~* Fibroid tumours of the uterus incompatible with pregnancy.~* Malformations of the reproductive organs incompatible with pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- OHSS high risk patients (Type: EXPERIMENTAL): Triptorelin 0.2 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Velphoro and Impact on the Oral Cavity and Gut Microbiome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Suffering from hyperphosphatemia~* Current treatment with a stable dose of a non-iron containing phosphate binder,~* No or only parenteral iron application~* Age of ≥ 18 years~* Written informed consent prior to study participation~* The subject is willing and able to follow the procedures outlined in the protocol~Control group:~* Normal renal function~* No hyperphosphatemia~* Age- and sex-matched and oral disease status-matched (dental caries and periodontal disease) in comparison to the hyperphosphatemia group~* Written informed consent prior to study participation~* The subject is willing and able to follow the procedures outlined in the protocol~Exclusion Criteria:~* Age less than 18 years~* Currently on oral iron application~* Antibiotic treatment within the last two months~* Severe medical events within the last three months~* Planned surgery for the duration of the sampling~* Acute/chronic gastrointestinal infections~* Smokers~* Oral candidiasis~* Oral cancer~* Pregnant and lactating females~* Haemochromatosis history~* Committed to an institution by legal or regulatory order~* Participation in a parallel interventional clinical trial~* Receipt of an investigational drug within 30 days prior to inclusion into this study~* The subject is mentally or legally incapacitated~Only for the patient group:~* Never got any phosphate binder~* Allergy to Velphoro®~* Celiac disease or any other chronic inflammatory bowel disease~* Previous major surgery in the gastrointestinal tract

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- hemodialysis patients with hyperphosphatemia (Type: None): * dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool~* Velphoro® medication
- control group (Type: None): - dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Natural History of Anterior Compartment Pressures of the Thigh Following Femur Fracture

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* femur fracture~* age 18 and older~Exclusion Criteria:~* patients who are not candidates for surgical repair of femur fracture~* patients not expected to survive more than 1 week

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Needle Insertion into Femur (Type: OTHER): Data gathering with monitoring of pressures in the thigh via via needle in femur.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Proof-of-Concept Interventional Study With a Nasal Spray of JT-1 in Patients With Chronic Rhinitis or Chronic Sinusitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically diagnosed chronic allergic rhinitis or chronic sinusitis with no or a mild status of nasal polyp activity~* Disease lasting 12 weeks or longer~* Patients with moderate or severe symptoms (SNOT-22 score \>20)~* Male or female at least 18 years old~* Females in childbearing age are requested to make a pregnancy test and to confirm in writing to take contraceptive measures until Follow-up Visit (Day 49).~* Patient understands German~Exclusion Criteria:~* Severely purulent forms of sinusitis~* History of medication during the last four weeks~  * not allowed: antibiotics, systemic or topical steroids~ * allowed: nasal saline spray or irrigation, analgesics, decongestants, antihistamines~* Patient has a status of moderate or severe polyp activity in the nose~* Patient had sinus surgery in the past 6 months~* Patient needs O2 substitution~* Patient has cystic fibrosis~* Patient has primary ciliary dyskinesia~* Patient is demented or otherwise incapable of judgement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Jantar-1 (JT-1), 7% (w/w) aqueous solution (Type: EXPERIMENTAL): Dosing regimen: ad libitum between at least 2 doses, in the morning and in the evening, and at most 10 doses per day. A dose corresponds to two strokes of 100ul each per nostril.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Prolonging the Duration of Peripheral Venous Catheters in Cystic Fibrosis People

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of cystic fibrosis, made accordingly to the Cystic Fibrosis Foundation Guideline (Rosenstein BJ. J Pediatr 1998;132: 589-595)~* age of 18 years or more and ability to consciously express owns informed consent.~* have a prescription done by one of the CF Centre specialist Physicians of an IV antibiotic course of the expected duration of 2 weeks, due to a pulmonary exacerbation, with the association of ceftazidime 3 times daily and tobramycin once daily diluted in Normal Saline.~* absence of clinical conditions that contraindicate the administration of 350ml of Normal Saline in 30 minutes 3 times daily and of 400ml of Normal Saline in 40 minutes.~* no simultaneous anti-inflammatory therapy administered orally, IM or IV~* 30 days have passed from the end of the previous course.~* The IV course will be given to the subject as an inpatient, and he or she will be admitted to our hospital

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Higher concentration of antibiotic in NS
- B (Type: EXPERIMENTAL): Lower concentration of antibiotic in NS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Head Position Angles in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I and II children, 1-10 years of age~Exclusion Criteria:~* Facial deformity~* Pathological airway or cervical spine~* BMI\>35~* History of gastric reflux

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Children 1-5 years of age
- 2 (Type: ACTIVE_COMPARATOR): Children 6-10 years of age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has ongoing angioedema while taking an ACE inhibitor.~* The subject is between 18 and 80 years of age.~Exclusion Criteria:~* The subject has had angioedema while not taking an ACE inhibitor.~* The subject's angioedema only involves the bowel.~* The subject is known to be pregnant or has a positive urine pregnancy test.~* The subject has started on an oral contraceptive within the last 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- icatibant (Type: EXPERIMENTAL): 30 mg icatibant will be administered subcutaneously 0 and 6 hours after randomization
- Placebo (Type: PLACEBO_COMPARATOR): Subcutaneous at time 0 and 6 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women who report elevated fatigue following cancer diagnosis and treatment~Exclusion Criteria:~* Women who have medical conditions that may affect the immune system or are associated with baseline fatigue syndrome, and/or who use medications that affect the immune system or fatigue.~* Women with major affective disorders and those with sleep or pain disorders.~* Presence of medical conditions that may but subject at undue risk for experimental procedures.~* Chronic or recurring infections, symptoms of chronic heart failure, demyelinating disorders, and those taking immunosuppressive medications.~* Neoplastic disease other than primary breast cancer~* Compromised cardiovascular function~* Insulin-dependent diabetes~* Neurological disorder~* Peripheral neuropathy~* Pregnancy~* Use of psychotropic medications within 2 weeks of screening~* Abnormal screening laboratory findings (i.e., creatinine \> 1.4mg%; anemia; abnormal thyroid hormone; hematuria; elevated liver function tests, low protein or albumin; fasting glucose \>120mg%; elevated FTI or TSH; positive TB screening, HIV screening or hepatitis C).~* Smokers

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Study Arm (Type: EXPERIMENTAL): Please see intervention description

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: FemVue and Tubal Patency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pts ages 18-45 undergoing planned diagnostic laparoscopy with chromopertubation.~Exclusion Criteria:~* Adnexal mass \> 3.5cm or uterine size greater than 10 wks

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- FemVue device (Type: EXPERIMENTAL): FemVue would be used in conjunction with the laparoscopic chromopertubation to determine if it is as effective.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: To Study the Effect of Early Cooling in Acute Subdural Hematoma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-penetrating traumatic brain injury~* Glasgow Coma Scale (GCS) motor score ≤5 (not following commands)~* Estimated or known age 22-65 years~* Acute subdural hematoma requiring emergent craniotomy within 6 hours of initial injury~* Estimated time of injury to time to reach temp of 35°C\<6 hrs~Exclusion Criteria:~* Total GCS = 3 and bilateral fixed and dilated pupils~* Following commands after an initial period of coma (GSC motor score of 6)~* Known pre-existing neurological deficit (e.g., previous traumatic brain injury (TBI), stroke)~* Concomitant spinal cord injury~* Arrival temperature is \<35°C~* Hemodynamic instability (i.e., mean arterial pressure (MAP)\<60 millimetres of mercury (mmHg) for 30 minutes)~* Active cardiac dysrhythmia resulting in hemodynamic instability~* Pregnancy~* Duret hemorrhage~* Prisoner or Ward of the State~* Known history of clotting disorder (e.g., heparin induced thrombocytopenia, pulmonary embolism/deep venous thrombosis)~* Injury to other body organ where hypothermia would be precluded because of bleeding risk (e.g., grade 3 liver laceration; bowel laceration; flail lung or international normalized ratio (INR) \>1.4)~* Inability to obtain informed consent or utilize exception to informed consent for emergency research.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Hypothermia (Type: EXPERIMENTAL): Hypothermia to 33°C
- Normothermia (Type: ACTIVE_COMPARATOR): standard care - normothermia (37°C)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Coupling of Neural Activity and Retinal Blood Flow in Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged over 18 years, nonsmokers~* Normal findings in the medical history (except diabetes) and physical examination unless the investigator considers an abnormality to be clinically irrelevant~* normal laboratory findings (except diabetes associated parameters) unless the investigator considers the abnormality to be clinically irrelevant~* normal ophthalmic findings (except mild diabetic retinopathy), Ametropia less than 6 diopters~* inclusion criterion of patients is type I diabetes with non or mild non-proliferative retinopathy~Exclusion criteria~Any of the following will exclude a healthy subject from the study:~* Regular use of vasoactive drugs~* Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study~* Symptoms of a clinically relevant illness in the 3 weeks before the first study day~* Blood donation during the previous 3 weeks~* History or presence of any ocular pathology~* History or family history of epilepsy~* Systemic hypertension defined as systolic blood pressure \>150mmHg, diastolic blood pressure \>90mmHg~* Pregnancy~Any of the following will exclude a subject with diabetes from the study:~* Presence of non-insulin dependent diabetes, maturity onset diabetes of the young (MODY diabetes)~* History or presence of any other diabetes induced vascular pathologies or any other ocular condition other then diabetic retinopathy~* Best corrected visual acuity \<0.8~* Previous laser photocoagulation treatment~* Systemic hypertension defined as systolic blood pressure \>150mmHg, diastolic blood pressure \>90mmHg~* History or family history of epilepsy~* Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study~* Symptoms of a clinically relevant illness in the 3 weeks before the first study day~* Blood donation during the previous 3 weeks~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Diabetic retinopathy (Type: None): Patients with early insulin dependent diabetes and no or mild non-proliferative retinopathy
- healthy (Type: None): healthy control subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues